TY - JOUR
T1 - Omega-3 fatty acids in food and pharma
T2 - The enabling role of biotechnology
AU - Gillies, Peter J.
AU - Harris, William S.
AU - Kris-Etherton, Penny M.
N1 - Funding Information:
Disclosures P.J. Gillies holds patents on the use of omega-3 fatty acids derived from yeast, which he invented while an employee of the E.I. DuPont Company. W.S. Harris is a Senior Vice President at Health Diagnostic Laboratory, Inc., which offers blood omega-3 fatty acid testing clinically, and is the owner of OmegaQuant, LLC, which performs such testing for academic and clinical researchers. P.M. Kris-Etherton was a co-investigator on a research grant funded by GlaxoSmithKline to evaluate cardiovascular effects of Lovaza. She is a board member of the California Walnut Commission, MonaVie, Campbell Soup, Unilever, and Abunda, and her institution has received grants from the Peanut Institute, General Mills, the Almond Board of California & Hershey Foods, the National Cattleman’s Beef Association, and the Haas Avocado Board.
PY - 2011/12
Y1 - 2011/12
N2 - Omega-3 fatty acid research, which began as an epidemiologic curiosity, has generated perhaps the strongest dataset for any nutrient in regard to cardiovascular disease risk reduction. Although once a relatively descriptive field, advances in analytic techniques have opened up the biochemistry of omega-3 fatty acids and nutritional genomics in plants and man and have taken the field into the "omic" era. Despite this progress, fundamental questions remain unanswered, such as which fatty acid or metabolite thereof drives a given health benefit, how much of a given fatty acid should we consume, and how do we best source the requisite fatty acids? Of these questions, the ability to source omega-3 fatty acids in order to meet dietary guidelines has become a practical concern. The advent of novel oils from plants and single cell organisms as enabled by biotechnology may provide a solution to this problem and in the process open up new uses for omega-3 fatty acids in dietary supplements and drugs.
AB - Omega-3 fatty acid research, which began as an epidemiologic curiosity, has generated perhaps the strongest dataset for any nutrient in regard to cardiovascular disease risk reduction. Although once a relatively descriptive field, advances in analytic techniques have opened up the biochemistry of omega-3 fatty acids and nutritional genomics in plants and man and have taken the field into the "omic" era. Despite this progress, fundamental questions remain unanswered, such as which fatty acid or metabolite thereof drives a given health benefit, how much of a given fatty acid should we consume, and how do we best source the requisite fatty acids? Of these questions, the ability to source omega-3 fatty acids in order to meet dietary guidelines has become a practical concern. The advent of novel oils from plants and single cell organisms as enabled by biotechnology may provide a solution to this problem and in the process open up new uses for omega-3 fatty acids in dietary supplements and drugs.
KW - Dietary guidelines
KW - Dietary supplements, drugs
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - LDL, small dense LDL
KW - Lp-PLA
KW - Omega-3 index
KW - Resolvins
KW - Single cell oils, soybean oil
KW - Stearidonic acid
UR - http://www.scopus.com/inward/record.url?scp=81155133750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81155133750&partnerID=8YFLogxK
U2 - 10.1007/s11883-011-0206-z
DO - 10.1007/s11883-011-0206-z
M3 - Article
C2 - 21892757
AN - SCOPUS:81155133750
SN - 1523-3804
VL - 13
SP - 467
EP - 473
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 6
ER -